Structure-activity relationships of α-ketooxazole inhibitors of fatty acid amide hydrolase

Journal of Medicinal Chemistry

Volumn 50, Issue 14, 2007, Pages 3359-3368

  Hardouin, Christophe ^a   Kelso, Michael J ^a   Romero, F Anthony ^a   Rayl, Thomas J ^a   Leung, Donmienne ^a   Hwang, Inkyu ^a   Cravatt, Benjamin F ^a   Boger, Dale L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID AMIDASE INHIBITOR; OL 135; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG INHIBITION; DRUG STRUCTURE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

AMIDOHYDROLASES; ANIMALS; ENZYME INHIBITORS; MAGNETIC RESONANCE SPECTROSCOPY; OXAZOLES; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34447538150     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061414r     Document Type: Article

References (81)

1. Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling. Science 2002, 298, 1793-1796.
2. Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular Characterization of an Enzyme That Degrades Neuromodulatory Fatty Acid Amides. Nature 1996, 384, 83-87.
3. Giang, D. K.; Cravatt, B. F. Molecular Characterization of Human and Mouse Fatty Acid Amide Hydrolases. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2238-2242.
4. Patricelli, M. P.; Cravatt, B. F. Proteins Regulating the Biosynthesis and Inactivation of Neuromodulatory Fatty Acid Amides. Vitam. Horm. 2001, 62, 95-131.
5. Egertova, M.; Cravatt, B. F.; Elphick, M. R. Comparative Analysis of Fatty Acid Amide Hydrolase and CB1 Cannabinoid Receptor Expression in the Mouse Brain: Evidence of a Widespread Role for Fatty Acid Amide Hydrolase in Regulation of Endocannabinoid Signaling. Neuroscience 2003, 119, 481-496.
6. Patricelli, M. P.; Cravatt, B. F. Fatty Acid Amide Hydrolase Competitively Degrades Bioactive Amides and Esters through a Nonconventional Catalytic Mechanism. Biochemistry 1999, 38, 14125-14130.
7. Patricelli, M. P.; Cravatt, B. F. Clarifying the Catalytic Roles of Conserved Residues in the Amidase Signature Family. J. Biol. Chem. 2000, 275, 19177-19184.
8. Patricelli, M. P.; Lovato, M. A.; Cravatt, B. F. Chemical and Mutagenic Investigations of Fatty Acid Amide Hydrolase: Evidence for a Family of Serine Hydrolases with Distinct Catalytic Properties. Biochemistry 1999, 38, 9804-9812.
9. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor. Science 1992, 258, 1946-1949.
10. Boger, D. L.; Henriksen, S. J.; Cravatt, B. F. Oleamide: An Endogenous Sleep-Inducing Lipid and Prototypical Member of a New Class of Lipid Signalling Molecules. Curr. Pharm. Des. 1998, 4, 303-314.
11. Cravatt, B. F.; Lerner, R. A.; Boger, D. L. Structure Determination of an Endogenous Sleep-Inducing Lipid, cis-9-Octadecenamide (Oleamide): A Synthetic Approach to the Chemical Analysis of Trace Quantitites of a Natural Product. J. Am. Chem. Soc. 1996, 118, 580-590.
12. Cravatt, B. F.; Prospero-Garcia, O.; Suizdak, G.; Gilula, N. B.; Henriksen, S. J.; Boger, D. L.; Lerner, R. A. Chemical Characterization of a Family of Brain Lipids That Induce Sleep. Science 1995, 268, 1506-1509.
13. Boger, D. L.; Fecik, R. A.; Patterson, J. E.; Miyauchi, H.; Patricelli, M. P.; Cravatt, B. F. Fatty Acid Amide Hydrolase Substrate Specificity. Bioorg. Med. Chem. Lett. 2000, 10, 2613-2616.
14. Lang, W.; Qin, C.; Lin, S.; Khanolkar, A. D.; Goutopoulos, A.; Fan, P.; Abouzid, K.; Meng, Z.; Biegel, D.; Makriyannis, A. Substrate Specificity and Stereoselectivity of Rat Brain Microsomal Anandamide Amidohydrolase. J. Med. Chem. 1999, 42, 896-902.
15. Schmid, H. H. O.; Schmid, P. C.; Natarajan, V. N-Acylated Glycerophospholipids and Their Derivatives. Prog. Lipid Res. 1990, 29, 1-43.
16. Lambert, D. M.; Fowler, C. J. The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications. J. Med. Chem. 2005, 48, 5059-5087.
17. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of Pain Initiation by Endogenous Cannabinoids. Nature 1998, 394, 277-281.
18. Cravatt, B. F.; Lichtman, A. H. The Endogenous Cannabinoid System and Its Role in Nociceptive Behavior. J. Neurobiol 2004, 61, 149-160.
19. Walker, J. M.; Huang, S. M.; Stragman, N. M.; Tsou, K.; Sanudo-Pena, M. C. Pain Modulation by Release of the Endogenous Cannabinoid Anamdamide. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 12198-12203.
20. Gomez, R.; Navarro, M.; Ferrer, B.; Trigo, J. M.; Bilbao, A.; Del Arco, I.; Cippitelli, A.; Nava, F.; Piomelli, D.; Rodríguez de Fonseca, F. A Peripheral Mechanism for CB1 Cannabinoid Receptor Dependent Modulation of Feeding. J. Neurosci. 2002, 22, 9612-9617.
21. Williams, C. M.; Kirkham, T. C. Observational Analysis of Feeding Induced by δ-THC and Anandamide. Physiol. Behav. 2002, 76, 241-250.
22. Kathuria, S.; Gaetani, S.; Fegley, D.; Valino, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of Anxiety Through Blockade of Anandamide Hydrolysis. Nat. Med. 2003, 9, 76-81.
23. Melck, D.; Rueda, D.; Galve-Roberh, I.; De Petrocellis, L.; Guzmán, M.; Di Marzo, V. Involvement of the cAMP/Protein Kinase A Pathway and of Mitogen-Activated Protein Kinase in the Anti-proliferative Effects of Anandamide in Human Breast Cancer Cells. FEBS Lett. 1999, 463, 235-240.
24. Yamaji, K.; Sarker, K. P.; Kawahara, K.; Iino, S.; Yamakuchi, M.; Abeyama, K.; Hashiguchi, T.; Maruyama, I. Anandamide Induces Apoptosis in Human Endothelial Cells: Its Regulation System and Clinical Implications. Thromb. Haemostasis 2003, 89, 875-884.
25. Massa, F.; Marsicano, G.; Hermann, H.; Cannich, A.; Monory, K.; Cravatt, B. F.; Ferri, G. L.; Sibaev, A.; Storr, M.; Lutz, B. The Endogenous Cannabinoid System Protects against Colonic Inflammation. J. Clin. Invest. 2004, 113, 1202-1209.
26. Mallet, P. E.; Beninger, R. J. The Cannabinoid CB1 Receptor Antagonist SR141716A Attenuates the Memory Impairment Produced by Δ9- Tetrahydrocannabinol or Anandamide. Psychopharmacology 1998, 140, 11-19.
27. Panikashvili, D.; Simeonidou, C.; Ben Shabat, S.; Hanus, L.; Breuer, A.; Mechoulam, R.; Shohami, E. An Endogenous Cannabinoid (2-AG) is Neuroprotective after Brain Injury. Nature 2001, 413, 527-531.
28. Axelrod, J.; Felder, C. C. Cannabinoid Receptors and Their Endogenous Agonist, Anandamide. Neurochem. Res. 1998, 23, 575-581.
29. Di Marzo, V.; Bisogno, T.; De Petrocellis, L.; Melck, D.; Martin, B. R. Cannabimimetic Fatty Acid Derivatives: The Anandamide Family and Other "Endocannabinoids." Curr. Med. Chem. 1999, 6, 721-744.
30. Martin, B. R.; Mechoulam, R.; Razdan, R. K. Discovery and Characterization of Endogenous Cannabinoids. Life Sci. 1999, 65, 573-595.
31. Cheer, J. F.; Cadogan, A. K.; Marsden, C. A.; Fone, K. C. F.; Kendall, D. A. Modification of 5-HT2 Receptor Mediated Behaviour in the Rat by Oleamide and the Role of Cannabinoid Receptors. Neuropharmacology 1999, 38, 533-541.
32. Thomas, E. A.; Cravatt, B. F.; Sutcliffe, J. G. The Endogenous Lipid Oleamide Activates Serotonin 5-HT7 Neurons in Mouse Thalamus and Hypothalamus. J. Neurochem. 1999, 72, 2370-2378.
33. Boger, D. L.; Patterson, J. E.; Jin, Q. Structural Requirements for 5-HT2A and 5-HT1A Receptor Potentiation by the Biologically Active Lipid Oleamide. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4102-4107.
34. Lees, G.; Dougalis, A. Differential Effects of the Sleep-Inducing Lipid Oleamide and Cannabinoids on the Induction of Long-Term Potentiation in the CA1 Neurons of the Rat Hippocampus in Vitro. Brain Res. 2004, 997, 1-14.
35. Yost, C. S.; Hampson, A. J.; Leonoudakis, D.; Koblin, D. D.; Bornheim, L. M.; Gray, A. T. Oleamide Potentiates Benzodiazepine-Sensitive γ-Aminobutyric Acid Receptor Activity but Does Not Alter Minimum Alveolar Anesthetic Concentration. Anesth. Analg. 1998, 86, 1294-1299.
36. Huitrón-Reséndiz, S.; Gombart, L.; Cravatt, B. F.; Henriksen, S. J. Effect of Oleamide on Sleep and Its Relationship to Blood Pressure, Body Temperature, and Locomotor Activity in Rats. Exp. Neurol. 2001, 172, 235-243.
37. Boger, D. L.; Patterson, J. E.; Guan, X.; Cravatt, B. F.; Lerner, R. A.; Gilula, N. B. Chemical Requirements for Inhibition of Gap Junction Communication by the Biologically Active Lipid Oleamide. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 4810-4815.
38. Guan, X.; Cravatt, B. F.; Ehring, G. R.; Hall, J. E.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. The Sleep-Inducing Lipid Oleamide Deconvolutes Gap Junction Communication and Calcium Wave Transmission in Glial Cells. J. Cell Biol. 1997, 139, 1785-1792.
39. Mechoulam, R.; Fride, E.; Hanus, L.; Sheskin, T.; Bisogno, T.; Di Marzo, V.; Bayewitch, M.; Vogel, Z. Anandamide May Mediate Sleep Induction. Nature 1997, 389, 25-26.
40. Clement, A. B.; Hawkins, E. G.; Lichtman, A. H.; Cravatt, B. F. Increased Seizure Susceptibility and Proconvulsant Activity of Anandamide in Mice Lacking Fatty Acid Amide Hydrolase. J. Neurosci. 2003, 23, 3916-3923.
41. Cravatt, B. F.; Demarest, K.; Patricelli, M. P.; Bracey, M. H.; Giang, D. K.; Martin, B. R.; Lichtman, A. H. Supersensitivity to Anandamide and Enhanced Endogenous Cannabinoid Signaling in Mice Lacking Fatty Acid Amide Hydrolase. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 9371-9376.
42. Cravatt, B. F.; Saghatelian, A.; Hawkins, E. G.; Clement, A. B.; Bracey, M. H.; Lichtman, A. H. Functional Disassociation of the Central and Peripheral Fatty Acid Amide Signaling Systems. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 10821-10826.
43. Lichtman, A. H.; Shelton, C. C.; Advani, T.; Cravatt, B. F. Mice Lacking Fatty Acid Amide Hydrolase Exhibit a Cannabinoid Receptor-Mediated Phenotypic Hypoalgesia. Pain 2004, 109, 319-327.
44. Cravatt, B. F.; Lichtman, A. H. Fatty Acid Amide Hydrolase: An Emerging Therapeutic Target in the Endocannabinoid System. Curr. Opin. Chem. Biol. 2003, 7, 469-475.
45. Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Leung, D.; Acevedo, O.; Guimaráes, C. R. W.; Jorgensen, W. L.; Cravatt, B. F. Discovery of a Potent, Selective, and Efficacious Class of Reversible α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase as Analgesics. J. Med. Chem. 2005, 48, 1849-1856.
46. Boger, D. L.; Sato, H.; Lerner, A. E.; Austin, B. J.; Patterson, J. E.; Patricelli, M. P.; Cravatt, B. F. Trifluoromethyl Ketone Inhibitors of Fatty Acid Amide Hydrolase: A Probe of Structural and Conformational Features Contributing to Inhibition. Bioorg. Med. Chem. Lett. 1999, 9, 265-270.
47. Boger, D. L.; Sato, H.; Lerner, A. E.; Hedrick, M. P.; Fecik, R. A.; Miyauchi, H.; Wilkie, G. D.; Austin, B. J.; Patricelli, M. P.; Cravatt, B. F. Exceptionally Potent Inhibitors of Fatty Acid Amide Hydrolase: The Enzyme Responsible for Degradation of Endogenous Oleamide and Anandamide. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5044-5049.
48. De Petrocellis, L.; Melck, D.; Ueda, N.; Maurelli, S.; Kurahashi, Y.; Yamamoto, S.; Marino, G.; Di Marzo, V. Novel Inhibitors of Brain, Neuronal, and Basophilic Anandamide Amidohydrolase. Biochem. Biophys. Res. Commun. 1997, 231, 82-88.
49. Deutsch, D. G.; Omeir, R.; Arreaza, G.; Salehani, D.; Prestwich, G. D.; Huang, Z.; Howlett, A. Methyl Arachidonyl Fluorophosphonate: A Potent Irreversible Inhibitor of Anandamide Amidase. Biochem. Pharmacol. 1997, 53, 255-260.
50. Deutsch, D. G.; Lin, S.; Hill, W. A. G.; Morse, K. L.; Salehani, D.; Arreaza, G.; Omeir, R. L.; Makriyannis, A. Fatty Acid Sulfonyl Fluorides Inhibit Anandamide Metabolism and Bind to the Cannabinoid Receptor. Biochem. Biophys. Res. Commun. 1997, 231, 217-221.
51. Du, W.; Hardouin, C.; Cheng, H.; Hwang, I.; Boger, D. L. Heterocyclic Sulfoxide and Sulfone Inhibitors of Fatty Acid Amide Hydrolase. Bioorg. Med. Chem. Lett. 2005, 15, 103-106.
52. Edgemond, W. S.; Greenberg, M. J.; McGinley, P. J.; Muthians, S.; Campbell, W. B.; Hillard, C. J. Synthesis and Characterization of Diazomethylarachidonyl Ketone: An Irreversible Inhibitor of N- Arachidonylethanolamine Amidohydrolase. J. Pharmacol. Exp. Ther. 1998, 286, 184-190.
53. Fernando, S. R.; Pertwee, R. G. Evidence That Methyl Arachidonyl Fluorophosphonate Is an Irreversible Cannabinoid Receptor Antagonist. Br. J. Pharmacol. 1997, 121, 1716-1720.
54. Koutek, B.; Prestwich, G. D.; Howlett, A. C.; Chin, S. A.; Salehani, D.; Akhavan, N.; Deutsch, D. G. Inhibitors of Arachidonoyl Ethanolamide Hydrolysis. J. Biol. Chem. 1994, 269.
55. Patricelli, M. P.; Patterson, J. P.; Boger, D. L.; Cravatt, B. F. An Endogenous Sleep-Inducing Compound Is a Novel Competitive Inhibitor of Fatty Acid Amide Hydrolase. Bioorg. Med. Chem. Lett. 1998, 8, 613-618.
56. Patterson, J. E.; Ollmann, I. R.; Cravatt, B. F.; Boger, D. L.; Wong, C.-H.; Lerner, R. A. Inhibition of Oleamide Hydrolase Catalyzed Hydrolysis of the Endogenous Sleep-Inducing Lipid cis-9-Octadecenamide. J. Am. Chem. Soc. 1996, 1996, 5938-5945.
57. Tarzia, G.; Duranti, A.; Gatti, G.; Piersanti, G.; Tontini, A.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Mor, M.; Kathuria, S.; Piomelli, D. Synthesis and Structure-Activity Relationships of FAAH Inhibitors: Cyclohexylcarbamic Acid Biphenyl Esters with Chemical Modulation at the Proximal Phenyl Ring. ChemMedChem 2006, 1, 130-139.
58. Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Park, C.; Kathuria, S.; Piomelli, D. Design, Synthesis, and Structure-Activity Relationships of Alkylcarbamic Acid Aryl Esters, a New Class of Fatty Acid Amide Hydrolase Inhibitors. J. Med. Chem. 2003, 46, 2352-2360.
59. Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kathuria, S.; Piomelli, D. Cyclohexylcarbamic Acid 3′- or 4′-Substituted Biphenyl-3-yl Esters as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships, and Molecular Modeling Studies. J. Med. Chem. 2004, 47, 4998-5008.
60. Muccioli, G. G.; Fazio, N.; Scriba, G. K. E.; Poppitz, W.; Cannata, F.; Poupaert, J. H.; Wouters, J.; Lambert, D. M. Substituted 2-Thioxoimidazolidin-4- ones and Imidazolidine-2,4-diones as Fatty Acid Amide Hydrolase Inhibitors Templates. J. Med. Chem. 2006, 49, 417-425.
61. Leung, D.; Du, W.; Hardouin, C.; Cheng, H.; Hwang, I.; Cravatt, B. F.; Boger, D. L. Discovery of an Exceptionally Potent and Selective Class of Fatty Acid Amide Hydrolase Inhibitors Enlisting Proteome-Wide Selectivity Screening: Concurrent Optimization of Enzyme Inhibitor Potency and Selectivity. Bioorg. Med. Chem. Lett. 2005, 15, 1423-1428.
62. Hohmann, A. G.; Suplita, R. L.; Bolton, N. M.; Neeley, M. H.; Fegley, D.; Mangieri, R.; Krey, J.; Walker, J. M.; Holmes, P. V.; Crystal, J. D.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; Piomelli, D. An Endocannabinoid Mechanism for Stress-Induced Analgesia. Nature 2005, 435, 1108-1112.
63. Alexander, J. P.; Cravatt, B. F. Mechanism of Carbamate Inactivation of FAAH: Implications for the Design of Covalent Inhibitors and in Vivo Functional Probes for Enzymes. Chem. Biol. 2005, 12, 1179-1187.
64. Lichtman, A. H.; Leung, D.; Shelton, C. C.; Saghatelian, A.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Reversible Inhibitors of Fatty Acid Amide Hydrolase That Promote Analgesia: Evidence for an Unprecedented Combination of Potency and Selectivity. J. Pharmacol. Exp. Ther. 2004, 311, 441-448.
65. See also: Zhang, D.; Saraf, A.; Kolasa, T.; Bhatia, P.; Zheng, G. Z.; Patel, M.; Lannoye, G. S.; Richardson, P.; Stewart, A.; Rogers, J. C.; Brioni, J. D.; Surowy, C. S. Fatty Acid Amide Hydrolase Inhibitors Display Broad Selectivity and Inhibit Multiple Carboxylesterases as Off-Targets. Neuropharmacology, in press.
66. Alexander, J. P.; Cravatt, B. F. The Putative Endocannabinoid Transport Blocker LY2183240 Is a Potent Inhibitor of FAAH and Several Other Brain Serine Hydrolases. J. Am. Chem. Soc. 2006, 128, 9699-9704.
67. Boger, D. L.; Miyauchi, H.; Hedrick, M. P. α-Keto Heterocycle Inhibitors of Fatty Acid Amide Hydrolase: Carbonyl Group Modification and α-Substitution. Bioorg. Med. Chem. Lett. 2001, 11, 1517-1520.
68. Chang, L.; Luo, L.; Palmer, J. A.; Sutton, S.; Wilson, S. J.; Barbier, A. J.; Breitenbucher, J. G.; Chaplan, S. R.; Webb, M. Inhibition of Fatty Acid Amide Hydrolase Produces Analgesia by Multiple Mechanisms. Br. J. Pharmacol. 2006, 148, 102-113.
69. Romero, F. A.; Hwang, I.; Boger, D. L. Delineation of a Fundamental α-Ketoheterocycle Substituent Effect for Use in the Design of Enzyme Inhibitors. J. Am. Chem. Soc. 2006, 68, 14004-14005.
70. Romero, F. A.; Du, W.; Hwang, I.; Rayl, T. J.; Leung, D.; Hoover, H. S.; Cravatt, B. F.; Boger, D. L. Potent and Selective α-Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase. J. Med. Chem. 2007, 50, 1058-1068.
71. Leung, D.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Discovering Potent and Selective Reversible Inhibitors of Enzymes in Complex Proteomes. Nat. Biotechnol. 2003, 21, 687-691.
72. Sonogashira, K.; Tohda, Y.; Hagihara, N. A Convenient Synthesis of Acetylenes: Catalytic Substitutions of Acetylenic Hydrogen with Bromoalkenes, Iodoarenes, and Bromopyridines. Tetrahedron Lett. 1975, 16, 4467-4470.
73. Saikachi, H.; Kitagawa, T.; Sasaki, H.; Van Leusen, A. M. Synthesis of Furan Derivatives. LXXXV. Condensation of Heteroaromatic Aldehydes with Tosylmethyl Isocyanide. Chem. Pharm. Bull. 1969, 27, 793-796.
74. Harn, N. K.; Gramer, C. J.; Anderson, B. A. Acylation of Oxazoles by the Copper-Mediated Reaction of Oxazol-2-ylzinc Chloride Derivatives. Tetrahedron Lett. 1995, 36, 9453-9456.
75. Dondoni, A.; Fantin, G.; Fogagnolo, M.; Medici, A.; Pedrini, P. Synthesis of (Trimethylsily 1)thiazoles and Reactions with Carbonyl Compounds. Selectivity Aspects and Synthetic Utility. J. Org. Chem. 1988, 53, 1748-1761.
76. Dondoni, A.; Mastellari, A. R.; Medici, A.; Negrini, E.; Pedrini, P. Synthesis of Stannylthiazoles and Mixed Stannylsilylthiazoles and Their Use for a Convenient Preparation of Mono- and Bis-Halothiazoles. Synthesis 1986, 757-760.
77. Pocar, D.; Stradi, R.; Trimarco, P. Enamines from Cyclopropylketones. Tetrahedron 1975, 31, 2427-2429.
78. Yovell, J.; Hirsch, D.; Sarel, S. Acid-Catalyzed Addition of Secondary Amines to Cyclopropyl Ketones. Mass Spectra of Some Cyclic Aminobutyrophenones. J. Org. Chem. 1977, 42, 850-855.
79. Davis, F. A.; Vishwakarma, L. C.; Billmers, J. M.; Finn, J. Synthesis of α-Hydroxy Carbonyl Compounds (Acyloins): Direct Oxidation of Enolates Using 2-Sulfonyloxaziridines. J. Org. Chem. 1984, 49, 3241-3243.
80. Patricelli, M. P.; Lashuel, H. A.; Giang, D. K.; Kelly, J. W.; Cravatt, B. F. Comparative Characterization of a Wild Type and Transmembrane Domain-Deleted Fatty Acid Amide Hydrolase: Identification of the Transmembrane Domain as a Site for Oligomerization. Biochemistry 1998, 37, 15177-15187.
81. For 2b, MW = 334, four H-bond acceptors, and c log P = 4.11. For 5hh, MW = 369, four H-bond acceptors, and c log P = 4.61. For 11j, MW = 354, four H-bond acceptors, c log P = 4.12, and five rotatable bonds.